Program
remdesivir
Also written as “Remdesivir”, “Remdesivir (RDV)” and “RDV”.
Its studies are mostly in COVID-19, led by 4 companies.
Drug pageRemdesivir: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 60 open or running | phase 3since Feb 28, 2020 | Feb 28, 2020 | none ahead |
| Biomed Industriesits history only | 10 open or running | phase 1since Jul 13, 2020 | Jul 13, 2020 | none ahead |
| Dr. Md. Alimur Reza | 10 open or running | phase 2since Oct 20, 2020 | Oct 20, 2020 | none ahead |
| Pfizerits history only | 11 open or running | phase 3since May 5, 2025 | May 5, 2025 | Sep 28, 2027phase 3 · NCT07013474 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Md. Alimur Reza only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named remdesivirINNProposed as its International Nonproprietary Name in WHO's List 116
- Oct 20, 2020First study: phase 2 study in COVID-19First studyNCT04596839 · 60 enrolled · Bangladesh
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor”ChEMBL 37, by rule
Studies
The one study Dr. Md. Alimur Reza leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04596839COVID-19 · Bangladesh | 2 | Completed | Apr 30, 2021 | 60 |
How it is read
Names in the registry
- “Remdesivir”, 5 entries
- “remdesivir”, 1 entry
- “Remdesivir (RDV)”, 1 entry
- “RDV”, 1 entry
- “Drug: GS-5734 - 1.00 mg/kg”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.